KR20220079878A - Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴 헤테로비시클릭 화합물 - Google Patents

Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴 헤테로비시클릭 화합물 Download PDF

Info

Publication number
KR20220079878A
KR20220079878A KR1020227013487A KR20227013487A KR20220079878A KR 20220079878 A KR20220079878 A KR 20220079878A KR 1020227013487 A KR1020227013487 A KR 1020227013487A KR 20227013487 A KR20227013487 A KR 20227013487A KR 20220079878 A KR20220079878 A KR 20220079878A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
mmol
dichloro
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227013487A
Other languages
English (en)
Korean (ko)
Inventor
파브리지오 지오르다네토
모르텐 외스테르가드 얀센
비쉬와나뜨 요기니
로저 존 스노우
Original Assignee
디.이. 쇼우 리서치, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디.이. 쇼우 리서치, 엘엘씨 filed Critical 디.이. 쇼우 리서치, 엘엘씨
Publication of KR20220079878A publication Critical patent/KR20220079878A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227013487A 2019-10-07 2020-10-06 Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴 헤테로비시클릭 화합물 Withdrawn KR20220079878A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962911648P 2019-10-07 2019-10-07
US62/911,648 2019-10-07
PCT/US2020/054393 WO2021071832A1 (en) 2019-10-07 2020-10-06 Aryl heterobicyclic compounds as kv1.3 potassium shaker channel blockers

Publications (1)

Publication Number Publication Date
KR20220079878A true KR20220079878A (ko) 2022-06-14

Family

ID=75438321

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227013487A Withdrawn KR20220079878A (ko) 2019-10-07 2020-10-06 Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴 헤테로비시클릭 화합물

Country Status (11)

Country Link
US (1) US20230049231A1 (cg-RX-API-DMAC7.html)
EP (1) EP4041405A4 (cg-RX-API-DMAC7.html)
JP (1) JP7780440B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220079878A (cg-RX-API-DMAC7.html)
CN (1) CN114828963B (cg-RX-API-DMAC7.html)
AU (1) AU2020362118A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006292A2 (cg-RX-API-DMAC7.html)
CA (1) CA3157020A1 (cg-RX-API-DMAC7.html)
IL (1) IL291866A (cg-RX-API-DMAC7.html)
MX (1) MX2022004178A (cg-RX-API-DMAC7.html)
WO (1) WO2021071832A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116782894A (zh) 2020-10-06 2023-09-19 D.E.肖研究有限责任公司 作为Kv1.3钾Shaker通道阻断剂的内酰胺化合物
US20250230172A1 (en) * 2021-10-13 2025-07-17 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
JP2026513122A (ja) * 2022-10-28 2026-04-23 上海深勢唯思科技有限責任公司 芳香族複素環式Kv1.3阻害剤、その製造方法及び用途
WO2025021167A1 (zh) * 2023-07-26 2025-01-30 上海汇伦医药股份有限公司 芳基含氮杂环化合物、药物组合物和应用
WO2025029769A1 (en) 2023-07-31 2025-02-06 Eli Lilly And Company Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same
WO2025161144A1 (zh) * 2024-01-29 2025-08-07 上海深势唯思科技有限责任公司 芳基杂环类Kv1.3抑制剂及其制备方法和用途
WO2026021011A1 (zh) * 2024-07-26 2026-01-29 浙江海正药业股份有限公司 芳基三环类衍生物及其制备方法和用途
TW202607004A (zh) * 2024-08-01 2026-02-16 大陸商浙江海正藥業股份有限公司 6,7-二氫-5H-吡咯並〔1,2a〕咪唑類衍生物及其製備方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
JP4377231B2 (ja) * 2001-11-05 2009-12-02 大日本住友製薬株式会社 新規なカルバペネム化合物
US6939968B2 (en) * 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
CN1856477A (zh) * 2003-09-23 2006-11-01 默克公司 异喹啉钾通道抑制剂
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TW201026708A (en) * 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
WO2011073273A1 (en) * 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators
WO2012155199A1 (en) * 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers

Also Published As

Publication number Publication date
CN114828963A (zh) 2022-07-29
CN114828963B (zh) 2026-05-01
CA3157020A1 (en) 2021-04-15
US20230049231A1 (en) 2023-02-16
BR112022006292A2 (pt) 2022-06-28
EP4041405A4 (en) 2023-10-18
MX2022004178A (es) 2022-06-16
AU2020362118A1 (en) 2022-04-21
JP7780440B2 (ja) 2025-12-04
EP4041405A1 (en) 2022-08-17
WO2021071832A1 (en) 2021-04-15
IL291866A (en) 2022-06-01
JP2022551199A (ja) 2022-12-07

Similar Documents

Publication Publication Date Title
JP7780440B2 (ja) Kv1.3カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物
KR20220079882A (ko) Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴 헤테로시클릭 화합물
JP7763271B2 (ja) Kv1.3カリウムシェーカーチャネル遮断剤としてのスピロインドリノン化合物
JP2025020196A (ja) Kv1.3カリウムシェーカーチャネル遮断薬としてのアリールメチレン複素環式化合物
KR20230082041A (ko) Kv1.3 칼륨 셰이커 채널 차단제로서의 락탐 화합물
CN114728177B (zh) 作为Kv1.3钾Shaker通道阻滞剂的芳基杂二环化合物
EA046803B1 (ru) АРИЛЬНЫЕ ГЕТЕРОБИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК БЛОКАТОРЫ КАЛИЕВОГО КАНАЛА Kv1.3 ТИПА SHAKER
CN112521372A (zh) 一种细胞凋亡蛋白抑制剂及其制备方法和用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202